简体
  • 简体中文
  • 繁体中文
×

热门资讯> 正文

Nanyang Biologics推进15亿美元纳斯达克上市计划

2026-08-11 21:03

  • The9 Limited (NASDAQ: NCTY) said on Tuesday that its Singapore investee Nanyang Biologics received SEC effectiveness for its Form F-4 registration statement, marking a key step toward its planned Nasdaq listing.
  • The proposed business combination values Nanyang Biologics at about $1.5B pre-transaction.
  • The company is expected to hold a 15%-16% stake in the combined company through its Gamenow subsidiary.
  • The Nasdaq listing remains subject to shareholder approval at the SPAC's Aug. 19 meeting and Nasdaq approval.
  • Share -3.82%

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
问答大全
（工作日09：30 - 次日05：30）
客户端：
关注我们：
  • 微信公众号二维码

© 2026 深圳市时代华盛网络科技有限公司版权所有 粤ICP备16068286号